We are thrilled to announce FutureMeds’ expansion in Germany. With the refurbishment work underway at our new Frankfurt location, our anticipation builds as we gear towards becoming operational by Q1 2024.
Frankfurt, a vibrant metropolis, is not just our new location; it is a strategic step in amplifying our clinical research reach and impact.
Besides being able to reach a diverse population, having an operational presence in Rhein-Main, a world-leading life sciences cluster, will enable us to forge closer ties with academic, industrial and regulatory players in the field of drug development and encourage DCT adoption across the continent by leading with example.
“Early 2024 the second German site will open in Frankfurt, supported by the experience and manpower of FutureMeds Berlin. In Frankfurt, we see not just a location, but a confluence where life science and partnerships can flourish, guided by shared visions of clinical research excellence.”
- Dr. med. Bettina Bergtholdt, Managing Director at FutureMeds Germany
As many as 180 nationalities call Frankfurt their home. The city’s central location, its culturally and ethnically diverse population, and its well-connected infrastructure provide a perfect setting for our new site and ambitions.
The potential of this location is further enhanced by a metropolitan population of over 796,000 people. Via our DCT solution, FutureMeds @home, our clients can boost patient experience and access patient populations outside the boundaries of the traditional catchment area of a site.
“With Frankfurt in our portfolio, we are able to reach and treat more patients across Germany. The Frankfurt area has well-established clinical trials and a willing patient population to support them. As an additional benefit, many of our clients are located in Frankfurt or nearby.”
- Dr. med. Bettina Bergtholdt, Managing Director at FutureMeds Germany
Frankfurt is home to some of the leading research institutions in the world, such as the Frauenhofer, Helmholtz, and Max Planck institutes. In addition, the region is home to renowned pharmaceutical corporations such as BioNTech, Sanofi, Merck, Fresenius, and Boehringer Ingelheim, as well as chemical giants including DuPont, Celanese, and Clariant. The Paul Ehrlich Institute, a key German regulator for vaccines and biomedicines, is also located in the region.
To facilitate ideal drug development conditions, the region has outstanding infrastructure and facilities tailored to the needs of the life sciences industry and covering the entire value chain.
With the refurbishment work at FutureMeds Frankfurt, we expect our new site to be up and running by March/April 2024.
About FutureMeds
FutureMeds is the 1st European Independent Dedicated DCT Site Network, offering high traditional trial and DCT readiness across the whole network and home nursing solutions in 18 countries.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help speed up drug development and patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.